Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
93.4 CHF | +0.85% | +1.10% | +9.98% |
May. 16 | Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15 | DP |
May. 16 | Novartis: presents results of tender offer for MorphoSysy | CF |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's enterprise value to sales, at 4.11 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.98% | 209B | B- | ||
+32.36% | 694B | C+ | ||
+31.17% | 593B | B | ||
-1.60% | 371B | C+ | ||
+20.07% | 331B | B- | ||
+6.04% | 290B | C+ | ||
+14.64% | 239B | B+ | ||
-3.27% | 209B | A+ | ||
+9.27% | 169B | C+ | ||
+0.45% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NOVN Stock
- Ratings Novartis AG